Synbiobeta 2023
This conference showcases the cutting-edge developments in biology that are transforming how we fuel, heal, and feed the world, and will include insights into cutting-edge medical advancements such as cell therapies, vaccines, and living medicines.
This conference showcases the cutting-edge developments in biology that are transforming how we fuel, heal, and feed the world, and will include insights into cutting-edge medical advancements such as cell therapies, vaccines, and living medicines.
We are curating the synbio for human health track at this event!
Come and visit our team at booth #30 to discover what is different about cell coding and the synthetic biology processes being utilised at bit.bio in comparison to traditional methods. Learn how our Cell Identity Coding Platform and our opti-ox™ technology enables fast, consistent and scalable manufacturing of human cells for research, drug discovery and cell therapies. Or come and join one of our sessions.
Agenda: Tuesday 23 May 2023
Main stage
Panel discussion | 8:55-9:25am
We are in the Age of Genetics. At last, we can address the underlying causes of disease after thousands of years of treating symptoms. Synthetic biology, founded on the ability to read, write, and run DNA, enables new therapeutic modalities to target and potentially cure our most challenging diseases. But what will it take for synbio therapeutics to become standard treatments? What challenges do we face in scaling, regulation, and adoption? What could the therapeutics landscape look like in the next 5 years? Join leading investors, academics, pharma executives, and synbio CEOs for a thought-provoking discussion on where the future of medicine will take us.
Speakers:
Welcome | 1:45 - 1:50pm
Mark Kotter, CEO and founder, bit.bio
Panel discussion | 1:50-2:10pm
How is SynBio Transforming Preclinical Drug Discovery?
Synthetic biology is impacting every aspect of drug discovery and development. By leveraging the latest technologies in single-cell analysis, high-throughput screening, human-relevant models and AI design, scientists can more quickly and effectively identify drug targets and compounds. What synbio technologies are seeing the most success? Can companies bring these tools together in collaborative tech stacks to further accelerate time to clinic? What are some of the challenges in bringing these tools into pharma pipelines and what opportunities are emerging in the next 2-3 years?
Fireside chat | 2:10-2:30pm
Bold Goals: How to Make Cell and Gene Therapies Frontline Treatment
It’s no secret that advanced medicines like cell and gene therapies are prohibitively expensive. While these offer potential cures for devastating diseases like cancer and sickle cell anaemia, the cost of these drugs can top $3 million per patient. Now the Biden Administration has issued executive orders to scale cell and gene therapies 10-fold in the next 20 years. What will it take to reach this bold goal? What factors are limiting the production of these life-saving therapies and what role can synbio play in accelerating time to market while reducing costs and improving efficacy? Join the discussion to learn what synbio breakthroughs are helping realise the promise of cell and gene therapies for all.
Break | 2:30-2:45pm
Panel discussion | 2:45-3:05pm
Better targeting, higher potency and payload delivery with synbio
Targeting and delivery of synbio are central challenges in developing novel therapeutic strategies. Finding and selectively targeting in the right organ, tumor, or cell type is essential. What are the current challenges and how are these being met? What novel synbio technologies are revealing novel targeting methodologies? How can we reach them with tools like lipid nano-particles or RNA? Join this session to learn how synbio is breaking new ground in getting advanced therapies to targets that have previously been impossible.
Panel discussion | 3:05-3:25pm
Platform or Therapeutics Company? Storytelling For the Investor Community
Synthetic biology looks to play a major role in the future of drug discovery, development and manufacturing. But for companies leveraging synbio technologies for human health, framing their roadmaps for investors can be a big challenge. There is no category for a company that is both a synbio and therapeutics company—the two business models are treated extremely differently. How can synbio companies developing therapeutic assets navigate the world of deep tech venture versus traditional pharma asset investment? How can entrepreneurs attract the right investors and how can synbio leaders communicate their story to the venture community?
Closing Remarks | 3:25-3:30pm
Mark Kotter, CEO and founder, bit.bio
Arrange a meeting